title: High-risk AML evidenced by a monoclonal antibody.
abstract: A monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this antigen was correlated to the clinical outcome. We found the expression of this antigen to predict a poor prognosis, when measured as survival of CR-patients and as survival after 1st relapse.
authors.affiliation: Finsen Institute, Department of Medicine, Gentofte Hospital, Copenhagen, Denmark.
authors.forename: S
authors.initials: S
authors.lastname: Avnstrøm
authors.forename: E
authors.initials: E
authors.lastname: Ralfkiaer
authors.forename: N E
authors.initials: NE
authors.lastname: Hansen
authors.forename: N I
authors.initials: NI
authors.lastname: Nissen
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000032:analysis; D001752:Blast Crisis / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface